As per the terms of the agreement NovImmune is expected to get an upfront payment and is eligible to receive clinical milestones and royalties on sales.
NovImmune said that its research team has generated anti-IL-17 antibody, which is currently in late preclinical development.
Recently, the IL-17 signaling pathway has received academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.
Jack Barbut, CEO, said: “We believe Genentech is the right partner for NovImmune for this program. Genentech brings an in-depth understanding of IL-17 biology and extensive experience in its ability to potentially identify patient populations that may benefit from such a compound thus maximising chances of successful development.”
James Sabry, vice president of Genentech, said: “Genentech is very pleased to have the opportunity to work with NovImmune on the development and potential commercialization of this anti-IL-17 antibody. We are hopeful that it has the potential to benefit patients across a range of autoimmune diseases.”